Conventional chemotherapeutic approaches to treating tumours can be hit-and-miss. One way to ensure successful treatment may be to go for the jugular of cancer-cell survival signalling as well.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout

References
Wendel, H. -G. et al. Nature 428, 332–337 (2004).
Vivanco, I. & Sawyers, C. L. Nature Rev. Cancer 2, 489–501 (2002).
Basu, S., Totty, N. F., Irwin, M. S., Sudol, M. & Downward, J. Mol. Cell 11, 11–23 (2003).
Manning, B. D. & Cantley, L. C. Trends Biochem. Sci. 28, 573–576 (2003).
Neshat, M. S. et al. Proc. Natl Acad. Sci. USA 98, 10314–10319 (2001).
Lin, T. A. et al. Science 266, 653–656 (1994).
Pause, A. et al. Nature 371, 762–767 (1994).
Li, S. et al. J. Biol. Chem. 278, 3015–3022 (2003).
Topisirovic, I. et al. Mol. Cell. Biol. 23, 8992–9002 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McCormick, F. Survival pathways meet their end. Nature 428, 267–269 (2004). https://doi.org/10.1038/428267a
Issue Date:
DOI: https://doi.org/10.1038/428267a
This article is cited by
-
Rapamycin Protects Spiral Ganglion Neurons from Gentamicin-Induced Degeneration In Vitro
Journal of the Association for Research in Otolaryngology (2019)
-
Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas
Journal of Neuro-Oncology (2011)
-
Targeting survivin via PI3K but not c-akt/PKB by anticancer drugs in immature neutrophils
Oncogene (2006)